Positive OS in exploratory analysis
Adenocarcinoma
+
PD
as best response to first-line therapy
*
.
Mellemgaard A,
et al
.
Eur J Cancer
. 2013;49(suppl. 2):Abstract 3409 and Oral presentation.
53
44
27
22
18
13
10
7
4
2
64
51
24
14
11
7
3
2
2
1
100
80
60
40
20
0
0 4 8 12 16 20 24 28 32 36
Probability of survival (%)
Time (months)
Nintedanib +
docetaxel
Placebo +
docetaxel
Median, mo
9.8
6.3
HR (95% CI)
0.62
(0.41 to 0.94)
p value
0.0246
43.0%
24.6%
21.5%
5.3%
Number at risk
Nintedanib
Placebo
* 18% of patients
